# OnCo record anbl1221 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/anbl1221/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "anbl1221", "NCT01767194" ;
  schema:name "ANBL1221"@en ;
  schema:alternateName "COG ANBL1221"@en ;
  schema:description "ANBL1221 found that adding the anti-GD2 antibody dinutuximab to irinotecan and temozolomide shrank relapsed neuroblastoma in about half of children, while adding temsirolimus almost never did, and chemo-immunotherapy became the standard salvage treatment."@en ;
  schema:url <https://onco.cc/trials/anbl1221/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01767194> ;
  onco:status "positive" ;
  onco:tag "soc-trials" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/neuroblastoma-high-risk/>, <https://onco.cc/cancers/neuroblastoma/>, <https://onco.cc/cancers/childhood-cancers/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/irinotecan/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/dinutuximab/>, <https://onco.cc/drugs/temsirolimus/>, <https://onco.cc/drugs/sargramostim/> ;
  onco:companies <https://onco.cc/companies/united-therapeutics/> ;
  onco:institutions <https://onco.cc/institutions/childrens-oncology-group/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017/>, <https://onco.cc/key-papers/paper-anbl1221-expansion-dinutuximab-gm-csf-mody-jco-2020/> .